This compound is a quinazoline diamine derivative used as a pharmaceutical intermediate in the manufacture of afatinib impurity standards. It features a dichlorophenyl substituent and a chiral oxolanyl ether group, with a molecular weight of 390.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 2044709-79-5
N4-(3-chloro-4-fluorophenyl)-7-(((3S)-tetrahydro-3-furanyl)oxy)-4,6-quinazolinediamine
active pharmaceutical ingredient metabolite
(R)-N4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-4,6-diamine
active pharmaceutical ingredient
Desfluoro-N-des(4-dimethylamino-2-en-1-oxo)butyl Afatinib
Afatinib impurity reference standard
(S)-N4-(3,4-Difluorophenyl)-7-((tetrahydrofuran-3-yl)oxy)quinazoline-4,6-diamine
Pharmaceutical intermediate for afatinib
6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-quinazolinol
pharmaceutical intermediate for afatinib impurities
Methyl 3-((2S,3R)-2-(4-(benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxoazetidin-3-yl)propanoate
Pharmaceutical intermediate
1-bromo-3,5-dimethoxybenzene
pharmaceutical intermediate
(2S)-2-(9H-Fuoren-9-ylmethoxycarbonylamino)-6-((1-(2-hydroxy-4,4-dimethyl-6-oxocyclohexen-1-yl)-3-methylbutylidene)amino)hexanoic acid
Peptide synthesis protected amino acid
4-N-(3,4-dichlorophenyl)-7-[(3S)-oxolan-3-yl]oxyquinazoline-4,6-diamine
BWMFVFPCIQVGNU-NSHDSACASA-N
C1COC[C@H]1OC2=C(C=C3C(=C2)N=CN=C3NC4=CC(=C(C=C4)Cl)Cl)N
—